<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
	
	<title>European Haemophilia Consortium (EHC)</title>
	<link rel="alternate" type="text/html" href="http://www.ehc.eu/" />
	<updated>2012-05-13T07:35:00+02:00</updated>
	<generator uri="http://www.typo3.com" version="4.5">TYPO3 - get.content.right</generator>
	<id>http://www.ehc.eu/</id>
	<subtitle>News</subtitle>
		
	
		
	<entry>
		<title>FDA Panel Endorses ’Quad’ Pill for HIV </title>
		<link rel="alternate" type="text/html" href="http://www.ehc.eu/press-release/archive/2012/05/13/fda-panel-endorses-quad-pill-for-hiv.html"/>
		<updated>2012-05-13T07:38:24+02:00</updated>
		<published>2012-05-13T07:38:24+02:00</published>
		<id>tag:ehc.eu,2012:article345</id>
		<author>
			<name></name>
		</author>
		<summary type="html" xml:base="http://www.ehc.eu/">
			<![CDATA[&lt;span style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 14px; FONT-FAMILY: arial; FONT-SIZE: 12px&quot;&gt;SILVER SPRING, Md. -- The FDA’s Antiviral Drugs Advisory Committee has voted 13 to 1 to recommend approval of Gilead Sciences’ new single-pill, once-daily regimen for HIV treatment.&lt;/span&gt; &lt;span style=&quot;FONT: italic 10px sans-serif; COLOR: #c75434&quot;&gt;&lt;link http://www.medpagetoday.com/HIVAIDS/HIVAIDS/32642?utm_content=&amp;utm_medium=email&amp;utm_campaign=DailyHeadlines&amp;utm_source=WC&amp;eun=g242881d0r&amp;userid=242881&amp;email=uschlenkrich@aol.com&amp;mu_id=5238156 _blank external-link-new-window&gt;&lt;img src=&quot;typo3/sysext/rtehtmlarea/res/accessibilityicons/img/external_link_new_window.gif&quot; alt=&quot;Opens external link in new window&quot; height=&quot;10&quot; width=&quot;14&quot; /&gt;full story&lt;/link&gt;&lt;/span&gt;
Source: medpagetoday]]>
		</summary>
	</entry>
		
	<entry>
		<title>Europe's biosimilars market could reach $3.99B in 5 years</title>
		<link rel="alternate" type="text/html" href="http://www.ehc.eu/press-release/archive/2012/05/13/europes-biosimilars-market-could-reach-399b-in-5-years.html"/>
		<updated>2012-05-13T07:35:58+02:00</updated>
		<published>2012-05-13T07:35:58+02:00</published>
		<id>tag:ehc.eu,2012:article344</id>
		<author>
			<name></name>
		</author>
		<summary type="html" xml:base="http://www.ehc.eu/">
			<![CDATA[&lt;font size=&quot;2&quot;&gt;The European biosimilars market is forecast to grow to $3.99 billion in 2017 from $172 million in 2010, according to a Frost &amp; Sullivan report. That is equivalent to compound growth of 56.7% a year. The expiration of patents for blockbuster biologics is expected to drive the growth. &lt;/font&gt;&lt;link http://r.smartbrief.com/resp/dEjaCMarocexcgzgfDfDbgfCzZrs?format=standard _blank external-link-new-window&gt;&lt;img src=&quot;typo3/sysext/rtehtmlarea/res/accessibilityicons/img/external_link_new_window.gif&quot; alt=&quot;Opens external link in new window&quot; height=&quot;10&quot; width=&quot;14&quot; /&gt;&lt;font size=&quot;2&quot;&gt;PharmaTimes (U.K.)&lt;/font&gt;&lt;/link&gt;
Source: AABBsmartbrief]]>
		</summary>
	</entry>
		
	<entry>
		<title>Calif. tattoo, piercing parlors to be subject to inspections</title>
		<link rel="alternate" type="text/html" href="http://www.ehc.eu/press-release/archive/2012/05/13/calif-tattoo-piercing-parlors-to-be-subject-to-inspections.html"/>
		<updated>2012-05-13T07:28:35+02:00</updated>
		<published>2012-05-13T07:28:35+02:00</published>
		<id>tag:ehc.eu,2012:article343</id>
		<author>
			<name></name>
		</author>
		<summary type="html" xml:base="http://www.ehc.eu/">
			<![CDATA[&lt;font size=&quot;2&quot;&gt;Tattoo and body-piercing establishments in California will face new standards and inspections in compliance with the state's Safe Body Art Act. The policy will be implemented in July. The move is intended to reduce the risk of blood-borne infections from tattoos and body-piercing procedures. &lt;/font&gt;&lt;link http://r.smartbrief.com/resp/dEbXCMarocewwNesfDfDbgfClFOM?format=standard _blank external-link-new-window&gt;&lt;img src=&quot;typo3/sysext/rtehtmlarea/res/accessibilityicons/img/external_link_new_window.gif&quot; alt=&quot;Opens external link in new window&quot; height=&quot;10&quot; width=&quot;14&quot; /&gt;&lt;font size=&quot;2&quot;&gt;The Fresno Bee (Calif.)&lt;/font&gt;&lt;/link&gt;
Source: AABBsmartbrief]]>
		</summary>
	</entry>
		
	<entry>
		<title>Vermont House calls on FDA to revise policy on MSM blood donations</title>
		<link rel="alternate" type="text/html" href="http://www.ehc.eu/press-release/archive/2012/05/13/vermont-house-calls-on-fda-to-revise-policy-on-msm-blood-donations.html"/>
		<updated>2012-05-13T07:15:48+02:00</updated>
		<published>2012-05-13T07:15:48+02:00</published>
		<id>tag:ehc.eu,2012:article342</id>
		<author>
			<name></name>
		</author>
		<summary type="html" xml:base="http://www.ehc.eu/">
			<![CDATA[&lt;font size=&quot;2&quot;&gt;The Vermont House has passed a resolution asking the FDA to revise its blood donor deferral policy for men who have sex with men. The resolution proposes the implementation of a one-year deferral period for MSM following last sexual contact. &lt;/font&gt;&lt;link http://r.smartbrief.com/resp/dDmzCMarocewdzjwfDfDbgfCaFdD?format=standard _blank external-link-new-window&gt;&lt;img src=&quot;typo3/sysext/rtehtmlarea/res/accessibilityicons/img/external_link_new_window.gif&quot; alt=&quot;Opens external link in new window&quot; height=&quot;10&quot; width=&quot;14&quot; /&gt;&lt;font size=&quot;2&quot;&gt;The Examiner (Washington, D.C.)/The Associated Press&lt;/font&gt;&lt;font color=&quot;#666666&quot; size=&quot;2&quot;&gt; &lt;/font&gt;&lt;/link&gt;
Source: AABBsmartbrief]]>
		</summary>
	</entry>
		
	<entry>
		<title>FDA Enters the ’Mad Cow’ Investigation </title>
		<link rel="alternate" type="text/html" href="http://www.ehc.eu/press-release/archive/2012/05/13/fda-enters-the-mad-cow-investigation.html"/>
		<updated>2012-05-13T07:08:35+02:00</updated>
		<published>2012-05-13T07:08:35+02:00</published>
		<id>tag:ehc.eu,2012:article341</id>
		<author>
			<name></name>
		</author>
		<summary type="html" xml:base="http://www.ehc.eu/">
			<![CDATA[&lt;span style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 14px; FONT-FAMILY: arial; FONT-SIZE: 12px&quot;&gt;WASHINGTON -- The FDA said it has joined the U.S. Department of Agriculture’s investigation of a confirmed case of bovine spongiform encephalopathy (BSE) in a California dairy cow.&lt;/span&gt; &lt;link http://www.medpagetoday.com/InfectiousDisease/PublicHealth/32371?utm_content=&amp;utm_medium=email&amp;utm_campaign=DailyHeadlines&amp;utm_source=WC&amp;eun=g242881d0r&amp;userid=242881&amp;email=uschlenkrich@aol.com&amp;mu_id=5238156 _blank external-link-new-window&gt;&lt;img src=&quot;typo3/sysext/rtehtmlarea/res/accessibilityicons/img/external_link_new_window.gif&quot; alt=&quot;Opens external link in new window&quot; /&gt;full story&lt;br /&gt;&lt;/link&gt;Source: medpagetoday]]>
		</summary>
	</entry>
		
	<entry>
		<title>FDA warns against combining hepatitis C treatment, some HIV drugs</title>
		<link rel="alternate" type="text/html" href="http://www.ehc.eu/press-release/archive/2012/04/29/fda-warns-against-combining-hepatitis-c-treatment-some-hiv-drugs.html"/>
		<updated>2012-04-29T08:17:21+02:00</updated>
		<published>2012-04-29T08:17:21+02:00</published>
		<id>tag:ehc.eu,2012:article340</id>
		<author>
			<name></name>
		</author>
		<summary type="html" xml:base="http://www.ehc.eu/">
			<![CDATA[&lt;font size=&quot;2&quot;&gt;The FDA is revising the label of boceprevir, a recently approved hepatitis C treatment, to warn about co-administration with certain HIV medicines. Taking boceprevir with some HIV drugs, including ritonavir, might increase the level of either virus in the blood, the agency said. &lt;/font&gt;&lt;link http://r.smartbrief.com/resp/dDcPCMarocevtPuMfDfDbgfCCNRe?format=standard _blank external-link-new-window&gt;&lt;img src=&quot;typo3/sysext/rtehtmlarea/res/accessibilityicons/img/external_link_new_window.gif&quot; alt=&quot;Opens external link in new window&quot; height=&quot;10&quot; width=&quot;14&quot; /&gt;&lt;font size=&quot;2&quot;&gt;Chicago Tribune/Reuters&lt;/font&gt;&lt;/link&gt;
Source: AABBsmartbrief&lt;font color=&quot;#666666&quot; size=&quot;2&quot;&gt;&nbsp;&lt;/font&gt;]]>
		</summary>
	</entry>
		
	<entry>
		<title>BSE is confirmed in Calif. dairy cow</title>
		<link rel="alternate" type="text/html" href="http://www.ehc.eu/press-release/archive/2012/04/29/bse-is-confirmed-in-calif-dairy-cow.html"/>
		<updated>2012-04-29T08:12:34+02:00</updated>
		<published>2012-04-29T08:12:34+02:00</published>
		<id>tag:ehc.eu,2012:article339</id>
		<author>
			<name></name>
		</author>
		<summary type="html" xml:base="http://www.ehc.eu/">
			<![CDATA[&lt;font size=&quot;2&quot;&gt;The USDA has confirmed a California dairy cow had bovine spongiform encephalopathy. USDA Chief Veterinary Officer Dr. John Clifford said the meat was not headed for the food supply. &lt;/font&gt;&lt;font size=&quot;2&quot;&gt;USA TODAY&lt;/font&gt;&lt;font color=&quot;#666666&quot; size=&quot;2&quot;&gt; (4/25), &lt;/font&gt;&lt;link http://r.smartbrief.com/resp/dCxtCMarocevmecYfDfDbgfCGIJJ?format=standard _blank external-link-new-window&gt;&lt;img src=&quot;typo3/sysext/rtehtmlarea/res/accessibilityicons/img/external_link_new_window.gif&quot; alt=&quot;Opens external link in new window&quot; height=&quot;10&quot; width=&quot;14&quot; /&gt;&lt;font size=&quot;2&quot;&gt;MSNBC/The Associated Press&lt;/font&gt;&lt;/link&gt;&lt;font color=&quot;#666666&quot; size=&quot;2&quot;&gt; (4/24), &lt;/font&gt;&lt;link http://r.smartbrief.com/resp/dCxtCMarocevmecYfDfDbgfCGIJJ?format=standard _blank external-link-new-window&gt;&lt;img src=&quot;typo3/sysext/rtehtmlarea/res/accessibilityicons/img/external_link_new_window.gif&quot; alt=&quot;Opens external link in new window&quot; height=&quot;10&quot; width=&quot;14&quot; /&gt;&lt;font size=&quot;2&quot;&gt;Reuters&lt;/font&gt;&lt;/link&gt;&lt;font color=&quot;#666666&quot; size=&quot;2&quot;&gt; &lt;/font&gt;
&lt;font color=&quot;#666666&quot; size=&quot;2&quot;&gt;Source: AABBsmartbrief&lt;/font&gt;]]>
		</summary>
	</entry>
		
	<entry>
		<title>Orphan-drug status is sought for hepatitis D treatment</title>
		<link rel="alternate" type="text/html" href="http://www.ehc.eu/press-release/archive/2012/04/29/orphan-drug-status-is-sought-for-hepatitis-d-treatment.html"/>
		<updated>2012-04-29T08:09:46+02:00</updated>
		<published>2012-04-29T08:09:46+02:00</published>
		<id>tag:ehc.eu,2012:article338</id>
		<author>
			<name></name>
		</author>
		<summary type="html" xml:base="http://www.ehc.eu/">
			<![CDATA[&lt;font size=&quot;2&quot;&gt;Medgenics sought orphan-drug status from the FDA for its hepatitis D treatment Infradure. The firm expects the designation to be confirmed next quarter. &lt;/font&gt;&lt;link http://r.smartbrief.com/resp/dCtICMarocevhJwQfDfDbgfCCOlu?format=standard _blank external-link-new-window&gt;&lt;img src=&quot;typo3/sysext/rtehtmlarea/res/accessibilityicons/img/external_link_new_window.gif&quot; alt=&quot;Opens external link in new window&quot; height=&quot;10&quot; width=&quot;14&quot; /&gt;&lt;font size=&quot;2&quot;&gt;Proactive Investors&lt;/font&gt;&lt;/link&gt;
Source: AABBsmartbrief]]>
		</summary>
	</entry>
		
	<entry>
		<title>  Strong demand seen for hemophilia, immune therapies</title>
		<link rel="alternate" type="text/html" href="http://www.ehc.eu/press-release/archive/2012/04/29/strong-demand-seen-for-hemophilia-immune-therapies.html"/>
		<updated>2012-04-29T08:01:55+02:00</updated>
		<published>2012-04-29T08:01:55+02:00</published>
		<id>tag:ehc.eu,2012:article336</id>
		<author>
			<name></name>
		</author>
		<summary type="html" xml:base="http://www.ehc.eu/">
			<![CDATA[&lt;font size=&quot;2&quot;&gt;Baxter International reported strong demand for devices and therapies for hemophilia, trauma and immune disorders, as well as for anesthesia products. Baxter is planning to build a facility in Georgia to broaden its plasma business. &lt;/font&gt;&lt;link http://r.smartbrief.com/resp/dCmzCMarocevadiAfDfDbgfCFKkt?format=standard _blank external-link-new-window&gt;&lt;img src=&quot;typo3/sysext/rtehtmlarea/res/accessibilityicons/img/external_link_new_window.gif&quot; alt=&quot;Opens external link in new window&quot; height=&quot;10&quot; width=&quot;14&quot; /&gt;&lt;font size=&quot;2&quot;&gt;Fox Business/Dow Jones Newswires&lt;/font&gt;&lt;/link&gt;&lt;font color=&quot;#666666&quot; size=&quot;2&quot;&gt; &lt;/font&gt;
&lt;font color=&quot;#666666&quot; size=&quot;2&quot;&gt;Source; AABBsmartbrief&lt;/font&gt;]]>
		</summary>
	</entry>
		
	<entry>
		<title> Hemophilia B drug submitted for FDA approval</title>
		<link rel="alternate" type="text/html" href="http://www.ehc.eu/press-release/archive/2012/04/29/hemophilia-b-drug-submitted-for-fda-approval.html"/>
		<updated>2012-04-29T07:57:42+02:00</updated>
		<published>2012-04-29T07:57:42+02:00</published>
		<id>tag:ehc.eu,2012:article335</id>
		<author>
			<name></name>
		</author>
		<summary type="html" xml:base="http://www.ehc.eu/">
			<![CDATA[&lt;font size=&quot;2&quot;&gt;Inspiration Biopharmaceuticals submitted IB1001 for consideration by the FDA. The bleeding-prevention therapy is an intravenous recombinant factor IX product for patients with hemophilia B. &lt;/font&gt;&lt;link http://r.smartbrief.com/resp/dCjCCMaroceuxXxofDfDbgfCZscx?format=standard _blank external-link-new-window&gt;&lt;img src=&quot;typo3/sysext/rtehtmlarea/res/accessibilityicons/img/external_link_new_window.gif&quot; alt=&quot;Opens external link in new window&quot; height=&quot;10&quot; width=&quot;14&quot; /&gt;&lt;font size=&quot;2&quot;&gt;Mass High Tech (Boston)&lt;/font&gt;&lt;/link&gt;&lt;font color=&quot;#666666&quot; size=&quot;2&quot;&gt; &lt;/font&gt;
&lt;font color=&quot;#666666&quot; size=&quot;2&quot;&gt;Source: AABBsmartbrief&lt;/font&gt;]]>
		</summary>
	</entry>
	
</feed>

